Items Tagged ‘belinostat’

July 24th, 2014

FDA Approves Beleodaq for Peripheral T-cell Lymphoma


The FDA announces its approval of Beleodaq (belinostat), a histone deacetylase inhibitor for treating peripheral T-cell lymphoma (PTCL), based on the results of the BELIEF study that found an overall response rate of nearly 26% among treated patients. PTCL accounts for about~15% of all non-Hodgkin’s lymphoma (NHL) cases in North America each year.  Historically treatment […]

View full entry

Tags: beleodaq, belinostat, News, ptcl, T-Cell Non-Hodgkin's Lymphoma